XML 80 R64.htm IDEA: XBRL DOCUMENT v3.22.0.1
Debt - 2018 Purchase Agreement and Indenture for Scilex - Additional Information (Details) - USD ($)
1 Months Ended 12 Months Ended
Dec. 14, 2020
Sep. 07, 2018
Nov. 30, 2019
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Feb. 15, 2022
Feb. 14, 2022
Apr. 30, 2021
Dec. 16, 2020
Debt Instrument [Line Items]                    
Loss on debt extinguishment     $ 27,800,000 $ 6,695,000 $ 51,939,000 $ 27,810,000        
Standby Letters of Credit                    
Debt Instrument [Line Items]                    
Maximum exposure under guarantor obligations   $ 35,000,000                
Scilex Pharmaceuticals, Inc                    
Debt Instrument [Line Items]                    
Minimum cash covenant         4,000,000.0       $ 10,000,000.0  
Scilex Pharmaceuticals, Inc | Maximum                    
Debt Instrument [Line Items]                    
Indebtedness in connection with an accounts receivable revolving loan facility $ 10,000,000.0                  
Scilex Pharmaceuticals, Inc | Optional Repurchases                    
Debt Instrument [Line Items]                    
Loss on debt extinguishment       14,000,000.0            
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026                    
Debt Instrument [Line Items]                    
Face value of loan   224,000,000   133,998,000 151,872,000          
Proceeds from issuance of senior long-term debt   140,000,000,000,000                
Net proceeds after deducting offering expenses and funding reserves and collateral   89,300,000                
Segregated reserve account funding   20,000,000.0                
Segregated collateral account funding   $ 25,000,000.0                
Release of restricted funds held in reserve and collateral account 45,000,000.0                  
Principal amount to be purchased $ 45,000,000.0                  
Purchase price, percentage of principal amount 100.00%                  
Cash purchase price, percentage of principal amount 100.00%                  
Reduction to aggregate principal amount       $ 40,000,000.0           $ 65,000,000.0
Debt instrument, interest rate, effective percentage       7.70%            
Amount of debt discount and debt issuance included in interest expense       $ 7,900,000 10,600,000 $ 15,000,000.0        
Principal payments       45,900,000 $ 69,800,000          
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026 | Subsequent Event                    
Debt Instrument [Line Items]                    
Principal amount to be purchased               $ 20,000,000.0    
Purchase price, percentage of principal amount               100.00%    
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026 | Minimum                    
Debt Instrument [Line Items]                    
Minimum cash covenant $ 10,000,000.0                  
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026 | Maximum                    
Debt Instrument [Line Items]                    
Principal amount to be purchased 20,000,000.0                  
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026 | ZTlido                    
Debt Instrument [Line Items]                    
Face value of loan       $ 28,000,000.0            
Percentage of outstanding principal holders can declare debt payable upon default   25.00%                
Percentage of outstanding payable due upon default   100.00%                
Compensating balance   $ 35,000,000                
Contingent liability   $ 25,000,000                
Percentage of principal amount outstanding holders need as an acceptance to replace letter of credit   80.00%                
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026 | ZTlido | Subsequent Event                    
Debt Instrument [Line Items]                    
Increase to aggregate principal amount             $ 28,000,000.0      
Percentage of net sales to predetermined threshold target sales             95.00%      
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026 | ZTlido | Maximum                    
Debt Instrument [Line Items]                    
Additional principal payments, sales threshold       95.00%            
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026 | February 15, 2019 - March 31, 2021 | ZTlido | Minimum                    
Debt Instrument [Line Items]                    
Quarterly principal payment as a percentage of net sales   10.00%                
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026 | February 15, 2019 - March 31, 2021 | ZTlido | Maximum                    
Debt Instrument [Line Items]                    
Quarterly principal payment as a percentage of net sales   20.00%                
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026 | Market approval by March 31, 2021 | ZTlido                    
Debt Instrument [Line Items]                    
Redemption price as a percentage of outstanding principal   101.00%                
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026 | Market approval by March 31, 2021 | ZTlido | Minimum                    
Debt Instrument [Line Items]                    
Quarterly principal payment as a percentage of net sales   15.00%                
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026 | Market approval by March 31, 2021 | ZTlido | Maximum                    
Debt Instrument [Line Items]                    
Quarterly principal payment as a percentage of net sales   25.00%                
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026 | October 1, 2022 - September 30, 2023 | ZTlido | Minimum                    
Debt Instrument [Line Items]                    
Additional principal payments, sales threshold   60.00%                
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026 | February 15, 2022 | ZTlido                    
Debt Instrument [Line Items]                    
Aggregate principal payment increase amount if cumulative net sales are not met   $ 28,000,000                
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026 | February 15, 2022 | ZTlido | Minimum                    
Debt Instrument [Line Items]                    
Additional principal payments, sales threshold   95.00%                
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026 | October 1, 2022 - September 30, 2023 | ZTlido | Minimum                    
Debt Instrument [Line Items]                    
Additional principal payments, sales threshold   80.00%                
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026 | Prior to August 15, 2026 | ZTlido                    
Debt Instrument [Line Items]                    
Period of notice for debt redemption   30 days                
Redemption price as a percentage of outstanding principal   100.00%                
Senior Notes | Scilex Pharmaceuticals, Inc | If Letter of Credit is Drawn On                    
Debt Instrument [Line Items]                    
Principal amount to be purchased 25,000,000.0                  
Senior Notes | Scilex Pharmaceuticals, Inc | If Scilex Does Not Receive Marketing Approval Letter On or Prior to July 1, 2023                    
Debt Instrument [Line Items]                    
Principal amount to be purchased $ 20,000,000.0                  
Senior Notes | Scilex Pharmaceuticals, Inc | December Optional Repurchase                    
Debt Instrument [Line Items]                    
Cash purchase price, percentage of principal amount 100.00%                  
Senior Notes | Scilex Pharmaceuticals, Inc | December Optional Repurchase | Maximum                    
Debt Instrument [Line Items]                    
Principal amount to be purchased $ 20,000,000.0                  
Senior Notes | Scilex Pharmaceuticals, Inc | February Optional Repurchase                    
Debt Instrument [Line Items]                    
Cash purchase price, percentage of principal amount 100.00%                  
Senior Notes | Scilex Pharmaceuticals, Inc | February Optional Repurchase | Maximum                    
Debt Instrument [Line Items]                    
Principal amount to be purchased $ 20,000,000.0                  
Senior Notes | Scilex Pharmaceuticals, Inc | April Optional Repurchase                    
Debt Instrument [Line Items]                    
Cash purchase price, percentage of principal amount 100.00%                  
Senior Notes | Scilex Pharmaceuticals, Inc | April Optional Repurchase | Maximum                    
Debt Instrument [Line Items]                    
Principal amount to be purchased $ 20,000,000.0                  
Subordinated Loan | Scilex Pharmaceuticals, Inc | Net Sales from Issue Date to December 31, 2021 Less than Specified Threshold | ZTlido | Subsequent Event                    
Debt Instrument [Line Items]                    
Face value of loan               $ 35,000,000